Challenges to the development of bryostatin-type anticancer drugs based on the activation mechanism of protein kinase Cδ

Medicinal Research Reviews
Kazuhiro IrieYu Nakagawa

Abstract

Protein kinase C (PKC) isozymes are widely recognized as targets for anticancer therapy, and recent investigations demonstrated that PKC activators are potential therapeutic candidates for Alzheimer's disease and acquired immune deficiency syndrome. However, concerns exist about their therapeutic uses because most PKC activators are potent tumor promoters. Bryostatin 1 (bryo-1) is a unique PKC activator with little tumor-promoting activities. Bryo-1 is currently undergoing clinical trials for the treatment of cancer. However, its limited availability from natural sources and difficulty in the synthesis hamper further studies on its mode of action and structural optimization. Although excellent practical methods for synthesizing several bryo-1-related compounds have been developed, the identification of synthetically more accessible compounds with bryo-1-like activity also provides a promising way to circumvent the problem of supply. The authors focused on the bryo-1's unique mechanism of activating PKCδ that plays a tumor suppressor role, and found that a simple and less lipophilic analogue (aplog-1) of the tumor-promoting aplysiatoxin showed PKCδ-activating behavior similar to bryo-1. Aplog-1 was easily synthesized in only 22 ...Continue Reading

References

Feb 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H zur HausenE Hecker
May 29, 1992·Journal of Medicinal Chemistry·K R GustafsonJ A Beutler
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·Y OnoY Nishizuka
Jan 1, 1987·Advances in Cancer Research·H Fujiki, T Sugimura
Nov 1, 1987·Immunobiology·H MohrA Plessing-Menze
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·P A WenderP M Blumberg
Mar 1, 1966·Journal of Bacteriology·G Henle, W Henle
Jan 3, 1995·Proceedings of the National Academy of Sciences of the United States of America·P A WenderB L Miller
Jul 1, 1996·Toxicon : Official Journal of the International Society on Toxinology·H NagaiY Hokama
Jun 1, 1997·Molecular and Cellular Biology·Z LuD A Foster
Nov 21, 1998·British Journal of Cancer·D J PropperA L Harris
Feb 24, 2001·Bioscience, Biotechnology, and Biochemistry·K IrieP A Wender
Jul 27, 2001·Biochemical and Biophysical Research Communications·G ZhuR O Messing
Feb 22, 2002·Cancer Chemotherapy and Pharmacology·Beverly A TeicherMargaret M Faul
Aug 28, 2002·Natural Product Reports·Karl J HaleMark Frigerio
Sep 13, 2002·Bioscience, Biotechnology, and Biochemistry·Akiko MasudaHajime Ohigashi
Nov 15, 2002·Journal of the American Chemical Society·Paul A WenderTim M Turner
Dec 10, 2002·Science·G ManningS Sudarsanam
Apr 1, 2004·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Desmond N Jackson, David A Foster

❮ Previous
Next ❯

Citations

Mar 19, 2013·Marine Drugs·Ying-Qing Wang, Ze-Hong Miao
Dec 18, 2013·Oncogene·R GargM G Kazanietz
Oct 3, 2015·Antiviral Research·Marta Martínez-BonetMaria Ángeles Muñoz-Fernández
Apr 14, 2016·Organic Letters·Jeremy Haynes-SmithKelvin L Billingsley
Mar 29, 2014·Chemical Record : an Official Publication of the Chemical Society of Japan ... [et Al.]·Kazuhiro Irie, Ryo C Yanagita
May 24, 2018·Future Medicinal Chemistry·Xiang Rong TianKirk R Gustafson
Aug 12, 2014·Chemical & Pharmaceutical Bulletin·Nami OhashiHirokazu Tamamura
Sep 11, 2014·Natural Product Reports·Mark S ButlerMatthew A Cooper
Apr 15, 2020·Marine Drugs·Maria Letizia CiavattaAndrea Waeschenbach
Oct 14, 2019·Journal of Pharmaceutical and Biomedical Analysis·Angela De SimoneVincenza Andrisano
Feb 3, 2021·Advances in Biological Regulation·Sachin Katti, Tatyana I Igumenova
Oct 11, 2020·Biochimica Et Biophysica Acta. General Subjects·Gan QiaoXiukun Lin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.